Stay updated on LASN01 Safety & Pharmacokinetics in Pulmonary Fibrosis Clinical Trial
Sign up to get notified when there's something new on the LASN01 Safety & Pharmacokinetics in Pulmonary Fibrosis Clinical Trial page.

Latest updates to the LASN01 Safety & Pharmacokinetics in Pulmonary Fibrosis Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check43 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check57 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check64 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.2%
- Check72 days agoChange DetectedThe study has completed both the Phase 1 and Phase 2a portions, with updates indicating successful administration of LASN01 in patients with IPF and PF-ILD, while previous recruitment statuses and estimated future locations have been removed.SummaryDifference4%
Stay in the know with updates to LASN01 Safety & Pharmacokinetics in Pulmonary Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LASN01 Safety & Pharmacokinetics in Pulmonary Fibrosis Clinical Trial page.